Frequently Asked Questions About ZYNLONTA®

ZYNLONTA® (loncastuximab tesirine-lpyl) is a prescription therapy for adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous therapy (refractory), who have already received 2 or more therapies for their cancer (R/R DLBCL).

Not an actual patient.

Your doctor may give you medicine before each infusion to decrease your chance of side effects. Your doctor may stop your treatment, delay your treatment, or change your dose of ZYNLONTA® if you have severe side effects.

Your doctor should do blood tests regularly to check for side effects of ZYNLONTA®. Your doctor will decide how many treatments you need.

General

Can I keep going with my daily routine while on ZYNLONTA®?

This may depend on your routine and how you do with treatment. Talk to your doctor’s office for more information.

Learn more about Discussions with Your Doctor

What if I miss a treatment?

If you miss a ZYNLONTA® treatment, be sure to alert your doctor immediately to discuss your options.

Learn more: Discussions with Your Doctor

How often will blood tests be done?

During treatment with ZYNLONTA®, your doctor will monitor your blood counts and run other laboratory tests through blood samples. Ask your doctor’s office to learn how often this testing will be required.

You will be monitored for infusion site reactions, infections, and skin reactions. You may also need CT scans to monitor the DLBCL.

Learn more: About ZYNLONTA® Infusions

How soon can I expect results?

About 50% of patients saw a response in 1.3 months. It took the other half longer to respond, up to 8.1 months. The range of response was between 1.1 months and 8.1 months.*

*In a clinical trial, 145 patients with DLBCL that has come back (relapsed) or did not respond to previous treatment (refractory) were treated with ZYNLONTA® to see how well it worked. The median time that it took for half of people to respond was 1.3 months. It took the other half longer to respond, up to 8.1 months. Learn about ZYNLONTA® clinical trial results.

Learn more: Get Results for ZYNLONTA®

What is the meaning of partial response, complete response, and overall response?

A partial response means that the signs of cancer have been reduced. Complete response means signs of cancer have disappeared. This does not always mean the cancer has been cured. Overall response includes both complete responses and partial responses.

Learn more about Find Result for ZYNLONTA®

What do relapse and refractory mean?

Relapse means previous therapies may have worked, but the cancer has come back at least once. Refractory means the cancer has not responded to past therapy/therapies.

Learn more: Discussions with Your Doctor

What kind of results can I expect with ZYNLONTA®?

About 48% of people saw results with ZYNLONTA®.

  • Nearly 24% had all signs of the cancer go away (a “complete response”)
    • That’s 35 out of 145 people
  • Nearly 24% had some of the cancer lessen (a “partial response”)
    • That’s 35 out of 145 people

Nearly 50% of patients saw a response in 1.3 months or 2 treatments

  • This is called the “median time.” That means it took half of people 1.3 months to have a response. And, it took the other half longer to respond, up to 8.1 months. The range of response was between 1.1 months and 8.1 months.

Nearly 50% of patients saw their results last for about 10.3 months

  • This is called the “median duration of response.” That means half of people’s cancer kept on responding to treatment without it growing or spreading for 10.3 months.
    • “Median duration of response” means that one half of people responded for a shorter amount of time, and the other half responded for a longer amount of time.

Learn more: Get Results for ZYNLONTA®

Can I receive ZYNLONTA® if I have already received certain treatments, such as a stem cell transplant or CAR-T therapy?

Yes. The ZYNLONTA® clinical trial included people with relapsed/refractory DLBCL who had already received a variety of therapies, including:

  • Chemotherapy
  • RITUXAN® (rituximab)
  • CAR-T therapy
  • Stem cell transplant

Talk with your doctor about your specific case and treatment history.

Learn more: Get Results for ZYNLONTA®

Who is ZYNLONTA® for?

ZYNLONTA® is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or did not respond to previous treatment (refractory), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma, and who have already received 2 or more treatments for their cancer.

It is not known if ZYNLONTA® is safe and effective in children.

The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.

Learn more: Get Results for ZYNLONTA®

What is ZYNLONTA®?

ZYNLONTA® is a prescription treatment for adults who have certain types of diffuse large B-cell lymphoma (or DLBCL) after 2 or more treatments did not work.

ZYNLONTA® is a targeted therapy that attaches to cancer cells and releases cancer-killing treatment. It is NOT traditional chemotherapy. It is what’s known as an antibody-drug conjugate (or ADC). There are different ADCs that can target different types of cancer cells. ZYNLONTA® is an ADC that targets the cancer cells of DLBCL.

The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.

Learn more: How ZYNLONTA® Targets Cancer

Expand

What is ZYNLONTA®?

ZYNLONTA® is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer.

It is not known if ZYNLONTA® is safe and effective in children.

The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of ZYNLONTA®?

ZYNLONTA® may cause serious side effects, including:

  • Fluid retention. Your body may hold too much fluid during treatment with ZYNLONTA®. This can be serious. Tell your healthcare provider if you develop new or worsening swelling or puffiness, weight gain, chest pain, shortness of breath, or trouble breathing
  • Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with ZYNLONTA® but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with ZYNLONTA®. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or any bruising or bleeding
  • Read full Important Safety Information
  • Infections. Serious infections, including infections that can cause death, have happened in people treated with ZYNLONTA®. Tell your healthcare provider right away if you have new or worsening signs or symptoms of infection
  • Skin reactions. Serious skin reactions have happened in people treated with ZYNLONTA®. Tell your healthcare provider if you get new or worsening skin reactions, including sensitivity to sunlight, skin rash, peeling, redness or irritation. You may burn more easily or get severe sunburns

The most common side effects of ZYNLONTA® include:

  • feeling tired or weak
  • skin rash
  • swelling
  • nausea
  • muscle or joint pain
  • increase in blood sugar (hyperglycemia)
  • changes in certain blood or laboratory tests

ZYNLONTA® may cause fertility problems in males which may affect your ability to father children. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of ZYNLONTA®.

What should I avoid while receiving ZYNLONTA®?

Avoid or limit your exposure to sunlight, including sunlight through glass, such as buildings or vehicle windows and artificial sunlight such as sunlamps or tanning beds. Exposure to sunlight during treatment with ZYNLONTA® can cause skin reaction or rash. Use sun protection measures such as sunscreen and wear loose-fitting clothes that cover your skin while out in sunlight.

Before you receive ZYNLONTA®, tell your healthcare provider about all of your medical conditions, including if you:

  • have an active infection or have had one recently
  • have liver problems
  • are pregnant or plan to become pregnant. ZYNLONTA® can harm your unborn baby

    Females who can become pregnant:

    • your healthcare provider may do a pregnancy test before starting treatment with ZYNLONTA®
    • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 9 months after the last dose of ZYNLONTA®. Talk to your healthcare provider about effective birth control. Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with ZYNLONTA®

    Males with female partners who can become pregnant:

    • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 6 months after the last dose of ZYNLONTA®
  • are breastfeeding or plan to breastfeed. It is not known if ZYNLONTA® passes into breast milk. Do not breastfeed during treatment with ZYNLONTA® and for 3 months after the last dose of ZYNLONTA®

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get new medicine.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to ADC Therapeutics at 1-855-690-0340.

Please see the full Prescribing Information for ZYNLONTA®, including Patient Information, for additional Important Safety Information.

What is ZYNLONTA®?

ZYNLONTA® is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer.

It is not known if ZYNLONTA® is safe and effective in children.

The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of ZYNLONTA®?

ZYNLONTA® may cause serious side effects, including:

  • Fluid retention. Your body may hold too much fluid during treatment with ZYNLONTA®. This can be serious. Tell your healthcare provider if you develop new or worsening swelling or puffiness, weight gain, chest pain, shortness of breath, or trouble breathing
  • Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with ZYNLONTA® but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with ZYNLONTA®. Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or above, or any bruising or bleeding
  • Read full Important Safety Information
  • Infections. Serious infections, including infections that can cause death, have happened in people treated with ZYNLONTA®. Tell your healthcare provider right away if you have new or worsening signs or symptoms of infection
  • Skin reactions. Serious skin reactions have happened in people treated with ZYNLONTA®. Tell your healthcare provider if you get new or worsening skin reactions, including sensitivity to sunlight, skin rash, peeling, redness or irritation. You may burn more easily or get severe sunburns

The most common side effects of ZYNLONTA® include:

  • feeling tired or weak
  • skin rash
  • swelling
  • nausea
  • muscle or joint pain
  • increase in blood sugar (hyperglycemia)
  • changes in certain blood or laboratory tests

ZYNLONTA® may cause fertility problems in males which may affect your ability to father children. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of ZYNLONTA®.

What should I avoid while receiving ZYNLONTA®?

Avoid or limit your exposure to sunlight, including sunlight through glass, such as buildings or vehicle windows and artificial sunlight such as sunlamps or tanning beds. Exposure to sunlight during treatment with ZYNLONTA® can cause skin reaction or rash. Use sun protection measures such as sunscreen and wear loose-fitting clothes that cover your skin while out in sunlight.

Before you receive ZYNLONTA®, tell your healthcare provider about all of your medical conditions, including if you:

  • have an active infection or have had one recently
  • have liver problems
  • are pregnant or plan to become pregnant. ZYNLONTA® can harm your unborn baby

    Females who can become pregnant:

    • your healthcare provider may do a pregnancy test before starting treatment with ZYNLONTA®
    • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 9 months after the last dose of ZYNLONTA®. Talk to your healthcare provider about effective birth control. Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with ZYNLONTA®

    Males with female partners who can become pregnant:

    • you should use effective birth control (contraception) during treatment with ZYNLONTA® and for 6 months after the last dose of ZYNLONTA®
  • are breastfeeding or plan to breastfeed. It is not known if ZYNLONTA® passes into breast milk. Do not breastfeed during treatment with ZYNLONTA® and for 3 months after the last dose of ZYNLONTA®

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get new medicine.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to ADC Therapeutics at 1-855-690-0340.

Please see the full Prescribing Information for ZYNLONTA®, including Patient Information, for additional Important Safety Information.

Connect with us